I Remember James Lovell
It was in 2009 and I was writing a story to mark the 40th anniversary of Apollo 11, the first moon landing.
My goal was to gather the recollections of as many of the original Apollo astronauts as possible.
I tracked Mr. Lovell down at his home in Lake Forest, Ill., and he gladly agreed to a telephone chat.
Apollo 13 moon mission leader James Lovell dies at 97
Mr. Lovell had also been part of the three-man crew of Apollo 8, the first mission to leave Earth and orbit the moon, a critical preparatory step to an actual landing.
During that December 1968 flight, one of the astronauts snapped the now iconic photo showing the beautiful blue Earth rising over a grey and lifeless lunar surface – an image that helped inspire the nascent environmental movement.
Seeing the Earth from such a great distance changed 'my understanding of my position in the universe,' he recalled. 'I looked back at my homeland and found out how small it was.'
In April, 1970, Lovell returned to the moon as commander of Apollo 13. This time, he and fellow astronaut Fred Haise were scheduled to land on the moon. But on the outbound voyage, an oxygen tank on the spacecraft's service module exploded. 'Houston, we've had a problem,' the crew radioed back to mission control. Plans for the landing had to be scrapped, and in next few days the astronauts and ground support worked frantically to bring the ship home before the power and oxygen ran out. When the capsule's parachutes opened over the Pacific Ocean, signalling their safe return, millions of anxious onlookers breathed a collective sigh of relief.
Mr. Lovell told me he initially considered Apollo 13 to be a failure and was extremely disappointed that he had lost his chance to walk on the moon. However, he recalled that, years later, while co-writing a book about the experience, he came to a different conclusion. 'It was really a triumph,' he said because it showed that people 'can change an almost certain catastrophe into a successful recovery.' All you need is the 'proper leadership, teamwork and initiative.'
His book became the basis for the acclaimed 1995 film Apollo 13 in which actor Tom Hanks portrayed Mr. Lovell. The Hollywood attention helped turn Mr. Lovell into a kind of pop-cult figure. Yet the good-natured retired astronaut, with a self-deprecating sense of humour, remained unfazed by his fame.
When our interview was drawing to a close, Mr. Lovell asked me a question.
'You work for a Toronto newspaper, right?' he quizzed.
Then he said, 'my father was Canadian – he came from Toronto.'
The senior Lovell had moved to the United States for work and ended up marrying an American woman. The father died when his son was a child, yet the boy maintained his ties to Canada.
'As a kid, I used to go see my grandparents [in Toronto] all the time.' He noted that his father is buried in the city's Mount Pleasant Cemetery.
Who would have imagined that this seemingly 'all-American' space hero has such deep Canadian roots.
Paul Taylor, Toronto
You can find more obituaries from The Globe and Mail here.
To submit a memory about someone we have recently profiled on the Obituaries page, e-mail us at obit@globeandmail.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
9 minutes ago
- CTV News
Scientists get a rare peek inside of an exploding star
This illustration provided by W.M. Keck Observatory depicts the insides of an exploding star. (Adam Makarenko/W. M. Keck Observatory via AP) NEW YORK — Scientists for the first time have spotted the insides of a dying star as it exploded, offering a rare peek into stellar evolution. Stars can live for millions to trillions of years until they run out of fuel. The most massive ones go out with a bang in an explosion called a supernova. ADVERTISEMENT Using telescopes that peer deep into space, researchers have observed many such explosions. The cosmic outbursts tend to jumble up a dying star's layers, making it hard for scientists to observe the inner structure. But that wasn't the case for the new discovery, a supernova called 2021yfj located in our Milky Way galaxy. The collapsing star's outermost layers of hydrogen and helium had peeled away long ago, which wasn't surprising. But the star's dense, innermost layers of silicon and sulfur had also shed during the explosion. 'We have never observed a star that was stripped to this amount,' said Northwestern University's Steve Schulze, who was part of the discovery team that published the research Wednesday in the journal Nature. The finding lends evidence to ideas scientists have about how large stars look near the end of their lives, organized into layers with lighter elements on the outside and heavier ones close to the core. 'Because so many of the layers had been stripped off this star, this basically confirmed what those layers were,' said Anya Nugent, who studies supernovas at the Harvard-Smithsonian Center for Astrophysics. She was not involved with the new research. It's not yet clear how this star got so whittled down — whether its layers were flung off violently in the final stages of its life or yanked away by a twin star. Future research may yield clues, though scientists acknowledged such an event may be tough to capture again. ___ Adithi Ramakrishnan, The Associated Press The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.


Globe and Mail
5 hours ago
- Globe and Mail
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Wednesday, September 10, 2025 Time: 1:00 PM - 1:30 pm, Eastern Time Location: Lotte New York Palace Hotel, Holmes I - 4th Floor Dr. Mendelsohn will highlight Vivani's portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance. More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Today, medication non-adherence affects approximately 50% of patients. Vivani's priority product candidate, NPM-139, is a miniature, six-month, subdermal, GLP-1 (semaglutide) implant under development for chronic weight management in obese or overweight subjects. NPM-139 has the added potential for once-yearly dosing. Vivani's emerging pipeline also includes NPM-115 (exenatide implant) for chronic weight management in obese and overweight individuals, and NPM-119, an exenatide implant program for the treatment of type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability and loss of efficacy. Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 Phase 1 study and reporting of study results, Vivani's emerging development plans for NPM-139, NPM-115, NPM-119 or Vivani's plans with respect its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-139, NPM-115, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities, including Vivani's ability to commence clinical development of NPM-139; risks related to the initiation, enrollment and conduct of Vivani's planned clinical studies and the results therefrom; or Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer info@ (415) 506-8462 Investor Relations Contact: Jami Taylor Investor Relations Advisor investors@ (415) 506-8462 Media Contact: Mark Corbae ICR Healthcare (203) 682-8288


Globe and Mail
5 hours ago
- Globe and Mail
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. 'I am thrilled to welcome Ramón to the leadership team at Aligos,' said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. 'As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón's extensive regulatory expertise will be a critical component as we think about the future of the program. His experience driving global regulatory strategies will help guide Aligos at this pivotal time.' 'I am excited to join the Aligos team as the company looks towards later-stage development,' stated Ramón Polo, MBA, PharmD, PhD, Senior Vice President, Head of Global Regulatory Affairs at Aligos. 'With my expertise leading global development and regulatory strategies at various pharma companies, I look forward to developing and implementing a comprehensive plan to aid in the continued development of ALG-000184.' Dr. Polo's diverse expertise includes leading and overseeing development teams, pharmacovigilance programs and regulatory strategies. He joins Aligos from Shionogi Inc., where he served as the Senior Vice President, Head of Global Regulatory Affairs, and focused on regulatory strategies for a number of different Therapeutic Areas, including infectious diseases. Previously, Dr. Polo was the Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs at Johnson & Johnson, where he played a key role in navigating the scientific, regulatory and global rollout challenges of the largest health crisis in a century as part of Johnson & Johnson's core team for the COVID-19 vaccine. Prior to this, Dr. Polo led the development strategy of treatments for influenza, RSV and hepatitis C at Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Polo received his PharmD, Master of Science and Ph.D. in Clinical Biochemistry from the Complutense University of Madrid in Spain. He obtained his Global MBA from the IESE Business School, University of Navarra, and attended the Program for Management Development at Harvard Business School. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered 'forward-looking statements,' including without limitation, statements regarding Aligos' financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos' capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Aligos Therapeutics Contact Jordyn Tarazi Vice President, Investor Relations & Corporate Communications +1 (650) 910-0427 jtarazi@ Media Contact Inizio Evoke Jake Robison Vice President This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.